April 18, 2008
Nereus Pharmaceuticals
Initiates Combination Clinical Trail for Proteasome Inhibitor NPI-0052 in Solid
Tumors
March 20, 2008
Nereus Pharmaceuticals
Initiates Clinical Trail of NPI-2358 in Non-Small Cell Lung Cancer Following
Encouraging Phase 1 Data
November 26, 2007
Nereus Pharmaceuticals
to Present Research at the Annual Meeting of the American Society of Hematology
October 16, 2007
Nereus Pharmaceuticals
NPI-0052 Named One of the Industry’s Top Ten Unpartnered Oncology Drug
Candidates
August 9, 2007
Nereus Pharmaceuticals
Raises $45 Million in Series D-2 Financing
April 16, 2007
The Multiple Myeloma Research Consortium and Nereus
Pharmaceuticals Initiate Clinical Trial Investigating NPI-0052 to Treat Multiple Myeloma
April 9, 2007
Nereus Pharmaceuticals to Present Data at the
American Association for Cancer Research 2007 Annual Meeting
June 28, 2006
Nereus Pharmaceuticals Appoints Dr. Charles While as Chief Business Officer
June 7, 2006
Nereus Pharmaceuticals Initiates Phase I Clinical
Trial for Anti-Cancer Compound NPI-2358
May 15, 2006
Nereus Pharmaceuticals Initiates Phase I Clinical
Trial for Anti-Cancer Proteasome Inhibitor
March 7, 2006
Nereus Pharmaceuticals Closes Second Tranche of $42.6 Million Financing
February 15, 2006
Nereus Pharmaceuticals Appoints Dr. Gary Shearman Chairman Of The Board Of Directors
January 4, 2005
Nereus Pharmaceutical Closes First Tranche of $42.6 Million Financing
November 19, 2003
Nereus Pharmaceuticals Reports Positive Preclinical Results of Vascular Targeting Anti-Cancer Compound
March 5, 2003
Nereus Pharmaceuticals Hires New Executives and Appoints Scientific Advisory Board Member
January 17, 2003
Scripps Scientists Discover Rich Medical Drug Resource in Deep Ocean Sediments
November 5, 2002
Nereus Pharmaceuticals Announces Keith Bostian Joins Its Scientific Advisory Board
October 8, 2002
Nereus Pharmaceuticals Builds-Up Research Team, Hires Seasoned Veteran as VP Research
July 16, 2002
Nereus Pharmaceuticals Announces Dr. Daniel Von Hoff Joins Its Scientific Advisory Board
May 7, 2002
Nereus Pharmaceuticals Assigned Patent For New Class Of Anti-Tumor Compounds
May 7, 2002
Nereus Announces Grant Of Patent For Anti-Inflammatory Drug Candidates
February 4, 2002
Nereus Pharmaceuticals Names Dr. Martin Rosenberg to Board of Directors
November 15, 2001
Nereus Announces Continued Expansion With Two New Personnel Appointments
October 23, 2001
Nereus Pharmaceuticals Awarded $850,000 SBIR Grant For Development of TNF-àlpha/IL-1 Synthesis Inhibitor
July 30, 2001
Nereus Raises $23.6 million in Second Round of Financing
October 24, 2000
Nereus Pharmaceuticals Appoints Frank V. AtLee to Board of Directors
July 31, 2000
Nereus Names Chief Scientific Officer and Vice President of Finance
April 17, 2000
Nereus Raises $8.6 million in First Round of Financing
|
